Modern therapeutics have reached unprecedented levels of sophistication beyond traditional drugs, including drugs for treating rare and disease conditions. Orphan drugs, biologics, and biosimilars are some of the significant classes of the advanced discoveries in the pharmaceutical sectors. The introduction of these categories substantially increased access to care, availability and outcomes.
What Are Orphan Drugs?
Orphan drugs are drugs that are developed to diagnose, prevent and treat rare diseases that affect a smaller number of people. As the number of patients affected is comparatively small, it is not lucrative for Pharmaceutical companies, developing these types of drugs is typically very expensive to obtain. Some Governments give incentives for developing Orphan Drugs to assist with innovation such as tax credits, research grants and achieving periods of exclusivity in the market.
Why Orphan Drugs are necessary
Even though most rare diseases only affect a few people, on a broader outlook, it ranges several billion people around the whole global population.
Most of these conditions are serious, progressive or life threatening and often available with limited treatment options. Orphan drugs support to change this gap and provide a method for patients to manage their disease, slow down the progression or improve their quality of life.
Challenges in Developing Orphan Drugs
- There are various challenges associated with developing orphan drugs, including:
- Limited patient population to conduct clinical trials on
- Very high research and development costs
- Limited knowledge about rare diseases
- Inability to generate a large amount of clinical evidence
However, there are many advancements in the area of genetic research and the use of precision medicine that are supporting the innovation of Orphan Drugs.
Orphan Drug Examples
Although the development is challenging, Orphan Drugs are currently in practice to treat Cystic fibrosis, Duchenne muscular dystrophy, Gaucher disease, Spinal muscular atrophy and many rare cancers and genetic disorders.
Effects on Patient and Healthcare System
Many patients will find that Orphan Drugs are the first effective treatment that has been available to them. While many of these drugs are very costly, over time they can help to decrease the financial burden on the healthcare system by decreasing the number of complications and hospitalizations associated with an occurred condition or disease.
What Are Biologics?
Biologics is a category of pharmaceuticals that are derived or manufactured from living organisms. It varies from synthetic pills, from small molecule pharmaceuticals or traditionally manufactured medications, which are commonly derived from chemical compounds, by their large and complex molecule structure, biologics are produced through means of biotechnology.
The development of biologics has revolutionized the way in which clinicians can treat numerous types of diseases by being able to specifically target biological pathways.
There are several different types of biologics, including:
1. Monoclonal Antibodies
2. Vaccines
3. Recombinant Proteins
4. Cell and Gene Therapies
5. Blood and Plasma-Derived Products
The process of development of biologics is comparatively complex and time-consuming, as it involves multi steps—cell engineering, protein production, purification, and extensive quality assurance testing before the approval for commercial distribution.
Potential benefits of biologics, including:
- Targeted Treatment Methods
- Increased Effectiveness for Difficult Disease Processes
- Decreased Effect on Healthy Cells
- Promises to Provide a Potential Personalized Medicine Approach
In which areas do we use biologics?
Biologics are integrated in the following areas of healthcare:
- Oncology
- Rheumatology
- Dermatology
- Gastroenterology
- Neurology
- Immunology
What Are Biosimilars?
Biosimilars are products (currently available) that are not identical to the original biologic, but rather similar to the original biologic, which was approved by the FDA in 2002. When the FDA evaluates the safety, effectiveness, and quality of these products, they will require a company to conduct extensive tests. Biosimilars differ from generics, as they do not share identical chemical compositions but active ingredients, and may have slight manufacturing variations. A review of the differences between biosimilars and generics is included below.
Generic Products vs. Biosimilar Products
Generic products are similar to original prescription drugs but vary on the basis of how they were manufactured, how they were tested, and their ingredient composition.
Biosimilars are product brands and will always be derived from some biological process. Although there may be many similarities, a biosimilar cannot be truly identical to another biosimilar because of biological variability.
Biosimilars Are Different from Generics in Terms of How They Will Be Approved
A biosimilar must prove its evidence of similarity to another biosimilar, and a comprehensive analysis must be performed to demonstrate that the two products are identical.
Unlike generics, there is limited approval data about biosimilars and thus numerous studies must be done before a biosimilar is approved by the FDA. A comparison of how biosimilars are approved and a list of the advantages of biosimilars to patients and the healthcare system are explained below.
Advantages of Biosimilars
- Cost Savings
Biosimilars can substantially lower the cost of biologic therapy, enables more patients utilize biosimilars.
- Increased Availability
With the diversified options for treatment methods, biologic therapy will be available to a larger number of patients without compromising on treatment effectiveness.
- Increased Competition
With the emerging market saturation, healthcare providers will gain choices, which will lead to better pricing and innovation in this sector.
- Increased Accessibility
By enabling affordability, it helps healthcare providers provide allocate treatments to massive populations, increasing treatment availability.
Conclusion
Orphan medicines, biological therapies, and biosimilars have changed how healthcare is perceived today. It facilitated targeted treatment options to bridge the access gaps and providing cutting-edge medications and biologic products to treat rare diseases. Orphan medicines provide the opportunity for patients to have access to new therapies, biologics offer new and innovative ways to treat disease, and biosimilars increase access and reduce the pricing of biologic products compared to their brand-name counterparts. Orphan drugs, biologics and biosimilars all contribute significantly to new wave of advancements in the pharmaceutical industry.
To read more, visit The Healthcare Insights.